Headlines about Codexis (NASDAQ:CDXS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Codexis earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.6702522973893 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Codexis (NASDAQ CDXS) opened at 5.55 on Friday. The stock’s 50 day moving average price is $5.38 and its 200 day moving average price is $4.79. Codexis has a 52-week low of $3.60 and a 52-week high of $5.75. The firm’s market capitalization is $268.20 million.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.13) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.13). The business had revenue of $10.30 million during the quarter, compared to the consensus estimate of $9.61 million. Codexis had a negative return on equity of 83.39% and a negative net margin of 40.70%. The company’s revenue for the quarter was down 35.6% compared to the same quarter last year. During the same period last year, the firm earned $0.12 earnings per share. Analysts expect that Codexis will post ($0.42) earnings per share for the current year.

CDXS has been the subject of several analyst reports. HC Wainwright set a $8.00 target price on Codexis and gave the stock a “buy” rating in a research note on Thursday, May 11th. Zacks Investment Research cut Codexis from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd. Jefferies Group LLC initiated coverage on Codexis in a research note on Wednesday, May 31st. They set a “buy” rating and a $8.00 target price for the company. ValuEngine raised Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, BidaskClub raised Codexis from a “hold” rating to a “buy” rating in a research note on Sunday, July 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $6.80.

COPYRIGHT VIOLATION NOTICE: “Codexis (CDXS) Receives News Impact Rating of 0.13” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/codexis-cdxs-receives-news-impact-rating-of-0-13/1535189.html.

About Codexis

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.